Filmmakers Anna Boden & Ryan Fleck to Bring #1 NY Times Bestselling Author Taylor Jenkins Reid's Upcoming Novel
HILLSBORO, Ore. & LOS ANGELES--(BUSINESS WIRE)--LAIKA has tapped filmmakers Anna Boden & Ryan Fleck (Captain Marvel, Masters of the Air) to adapt and direct a live action film based on the novel Atmosphere (Pub 6/3/25; Ballantine Books) by #1 NYT bestselling author Taylor Jenkins Reid (Daisy Jones and the Six). LAIKA's President, Live Action Film & Series Matt Levin made the announcement today.
The book is a sweeping romance between two pioneering female astronauts breaking into NASA in the early days of the shuttle program in the late '70s/early '80s. While the principal characters are fictionalized, the historical context and authenticity of the world-building is grounded in the spirit of films like Apollo 13, The Right Stuff, and Gravity. The epic story is set against the backdrop of the 1980s space shuttle program and shows the extraordinary lengths we go to in living and loving beyond our limits.
Atmosphere is a LAIKA production in association with Circle M+P. Anna Boden & Ryan Fleck are screenwriters and directors. Producers are Travis Knight, Matt Levin, Boden & Fleck, Taylor Jenkins Reid and Brad Mendelsohn. Jeremy Kipp Walker is executive producer.
'We couldn't be more excited to team up with three boundary-pushing creative voices on this very special film,' said Levin. 'From books like The Seven Husbands of Evelyn Hugo to Carrie Soto is Back, Taylor Jenkins Reid always captivates us with rich, emotionally complex characters and she is in peak form with Atmosphere. There are no better filmmakers to adapt Taylor's story for the screen than Ryan and Anna, who throughout their amazing careers have crafted deeply human stories set against canvases of stunning cinematic spectacle. We can't wait to see them bring Taylor's world of Atmosphere to life."
Taylor Jenkins Reid (subject of this week's TIME Magazine cover story) is the author of the New York Times Bestselling novels Carrie Soto Is Back, Malibu Rising, Daisy Jones and The Six and The Seven Husbands of Evelyn Hugo, as well as One True Loves, Maybe in Another Life, After I Do, and Forever, Interrupted. Her books have been chosen by Reese's Book Club, Read with Jenna, Indie Next, Best of Amazon, and Book of the Month. Daisy Jones and The Six was adapted as a limited series on Amazon Prime, garnering nine Emmy Award® nominations and two wins.
Anna Boden and Ryan Fleck are an Emmy®-winning Director/Writer/Producer duo with over two decades of collaboration, spanning a wide range of genres. Their latest film, Freaky Tales, is a genre-blending action comedy that premiered at the 2024 Sundance Film Festival. With roots in documentary and independent film, Boden and Fleck are also known for co-writing and directing the billion-dollar box office hit Captain Marvel. In 2006, Boden and Fleck made their feature debut with the award-winning film Half Nelson starring Ryan Gosling, who received an Academy Award® nomination for his performance. The film also won Movie of the Year at the AFI Awards, received Spirit Award nominations for Best Feature, Best Director, and Best Screenplay, and won Best Film, Director and Breakthrough Performance at the Gotham Awards. Next, they wrote and directed the independent film Sugar, an introspective sports drama following the life of a talented Dominican baseball player, which won Movie of the Year at the AFI Awards and received a Spirit Award nomination for Best Screenplay. In 2010, Boden and Fleck wrote and directed It's Kind of a Funny Story for Focus Features starring Keir Gilchrist, Zach Galifianakis and Zoë Kravitz. Mississippi Grind starred Ryan Reynolds and Ben Mendelsohn, who received a Spirit Award nomination for Best Actor.
In television, Boden & Fleck directed and executive produced the Emmy Award-winning limited series Mrs. America starring Cate Blanchett for FX. Other recent work includes Masters of the Air, executive produced by Tom Hanks, Steven Spielberg, and Gary Goetzman for Apple TV+ and Criminal, to be released later this year, which Boden & Fleck directed and executive produced for Amazon Studios.
Circle M+P executive produced Prime Video's Daisy Jones & The Six, based on client Taylor Jenkins Reid's bestselling novel, alongside Hello Sunshine. The breakout series debuted at No. 1 on Prime Video's Top 10 list in the U.S. and went on to receive nine Emmy nominations, winning two. Additionally, the company is known for executive producing the worldwide hit franchise, The Walking Dead.
Reps:
Taylor Jenkins Reid: WME, Park Fine & Brower Literary Management, Circle Management + Production, Jill Fritzo Public Relations and law firm Goodman, Genow, Schenkman, Smelkinson & Christopher.
Anna Boden & Ryan Fleck: WME, Entertainment 360 and law firm Jackoway Austen Tyerman Wertheimer Mandelbaum Morris Bernstein Trattner Auerbach Hynick Jaime LeVine Sample & Klein.
Circle M+P: Behr, Abramson, Levy & Johnson
LAIKA: CAA
About LAIKA
LAIKA was founded in 2005 in Oregon by President & CEO Travis Knight. The studio's five films: Missing Link (2019), Kubo and the Two Strings (2016), The Boxtrolls (2014), ParaNorman (2012) and Coraline (2009) have all been nominated for the Academy Award® for Outstanding Animated Feature. Kubo and the Two Strings won the BAFTA® Award for Best Animated Film and received an additional Oscar® nomination for Visual Effects. Missing Link was awarded the Golden Globe® for Best Animated Film. LAIKA was awarded a Scientific and Technology Oscar® in 2016 for its innovation in 3D printing. LAIKA is currently in production on its next animated film Wildwood. The studio is developing the animated feature films The Night Gardener, from an original idea by Bill Dubuque, creator of the hit series Ozark, and Piranesi, based on the NYT bestselling novel by Susanna Clarke. LAIKA's Live Action subsidiary has a range of projects in development including feature films based on the action thriller novel Seventeen by screenwriter John Brownlow and an original script Crumble, written and directed by Brian Duffield (Spontaneous) with Phil Lord and Chris Miller (Spider-verse films) producing. Oscar®-nominated screenwriter Jon Spaihts (Dune) will write and make his directorial debut on an untitled original live action film project.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
31 minutes ago
- Business Wire
Weedmaps Teams Up with Iconic LA Artist Robin Eisenberg for Cosmic, Female-Forward Apparel Collection
IRVINE, Calif.--(BUSINESS WIRE)-- Weedmaps, the leading cannabis technology company, is proud to unveil its latest limited-edition apparel and accessories collection in collaboration with renowned Los Angeles artist and animator Robin Eisenberg. Known for her ethereal, bold, and body-positive illustrations, Eisenberg brings her unmistakable cosmic aesthetic to the world of cannabis lifestyle wear, marking Weedmaps' first-ever female-forward fashion capsule. Following celebrated partnerships with Vans, Thrasher, and Adult Swim, Robin's newest creative venture channels the beauty of life's small moments infused with stoner-friendly whimsy and her signature galactic style. 'Robin's art captures the bold, inclusive spirit of cannabis culture. This collection celebrates creativity and community in a way that's genuinely unique to Weedmaps,' said SVP, Markets & Culture, Jonathan JJ Jones. The collection includes glow-in-the-dark ribbed socks, a raffia Leaf Cowboy Hat with enamel charms, an enamel pin pack, and cozy home essentials like the Robin Throw Blanket and quirky Catchall Tray. Apparel standouts include the 'Eye Heart' denim jacket, cowgirl-themed tees, and an interstellar 'Dreamstate' tank and tee series, each item designed to empower wearers to feel confident, expressive, and seen. With vibrant, inclusive designs and a cosmic-meets-cozy vibe, the Weedmaps x Robin Eisenberg collab is a celebration of cannabis culture, creativity, and confidence. The collection drops June 5th exclusively HERE. Please see images HERE. About WM Technology Founded in 2008, WM Technology operates Weedmaps, a leading cannabis marketplace for consumers, as well as a broad set of e-commerce and compliance software solutions for cannabis businesses and brands in U.S. state-legal markets. WM Technology holds a strong belief in the power of cannabis and the importance of enabling safe, legal access to consumers worldwide. Over the past 17 years, the Weedmaps marketplace has become a premier destination for cannabis consumers to discover and browse cannabis-related products, access daily dispensary deals, order ahead for pick-up and delivery by participating retailers (where applicable), and learn about the plant. The Company also offers e-commerce-enabling tools designed to help cannabis retailers and brands reach consumers, create business efficiency, and manage industry-specific compliance needs. The Company is committed to advocating for full U.S. legalization, industry-wide social equity, and continued education about the plant through key partnerships and cannabis subject matter experts. Headquartered in Irvine, California, WM Technology supports remote and hybrid work for eligible employees. Visit Weedmaps at
Business Wire
an hour ago
- Business Wire
MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ('MAIA', the 'Company'), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced a new partial response (PR) was identified in a patient after 20 months of treatment in its Phase 2 THIO-101 clinical trial evaluating ateganosine (THIO), sequenced with Regeneron's immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy. A partial response is defined as a decrease in tumor size of at least 30%. 'The patient remained on treatment and we observed stable disease for more than twenty months before the partial response was identified, highlighting the efficacy, safety and low toxicity of the treatment. Extended-term responses like this are not often seen in heavily pretreated patients in hard-to-treat diseases such as NSCLC, where the prognosis for the advanced-stage of the disease is typically poor,' said MAIA Chairman and CEO Vlad Vitoc, M.D. 'We confirmed this response with a second scan, and we are highly confident that ateganosine could become an outstanding therapeutic alternative for third-line NSCLC patients.' THIO-101 third line (3L) data cutoff from May 15, 2025, showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine in parts A and B of the trial. At the data cutoff, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival. Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months. 1 MAIA has announced the trial design for an expansion of its THIO-101 pivotal Phase 2 trial in NSCLC to assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous CPI treatment and chemotherapy. About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2'-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit Forward Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as 'may,' 'might,' 'will,' 'should,' 'could,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'project,' 'intend,' 'future,' 'potential,' or 'continue,' and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, 'MAIA,' 'Company,' 'we,' 'our,' and 'us' refers to MAIA Biotechnology, Inc. and its subsidiaries. 1
Yahoo
an hour ago
- Yahoo
MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial
CHICAGO, June 05, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced a new partial response (PR) was identified in a patient after 20 months of treatment in its Phase 2 THIO-101 clinical trial evaluating ateganosine (THIO), sequenced with Regeneron's immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy. A partial response is defined as a decrease in tumor size of at least 30%. "The patient remained on treatment and we observed stable disease for more than twenty months before the partial response was identified, highlighting the efficacy, safety and low toxicity of the treatment. Extended-term responses like this are not often seen in heavily pretreated patients in hard-to-treat diseases such as NSCLC, where the prognosis for the advanced-stage of the disease is typically poor," said MAIA Chairman and CEO Vlad Vitoc, M.D. "We confirmed this response with a second scan, and we are highly confident that ateganosine could become an outstanding therapeutic alternative for third-line NSCLC patients." THIO-101 third line (3L) data cutoff from May 15, 2025, showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine in parts A and B of the trial. At the data cutoff, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival. Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months.1 MAIA has announced the trial design for an expansion of its THIO-101 pivotal Phase 2 trial in NSCLC to assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous CPI treatment and chemotherapy. About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2'-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit Forward Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as "may," "might," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, "MAIA," "Company," "we," "our," and "us" refers to MAIA Biotechnology, Inc. and its subsidiaries. 1 Girard N, et al. J Thorac Onc 2009;12:1544-1549. View source version on Contacts Investor Relations Contact +1 (872) 270-3518ir@ Sign in to access your portfolio
